nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—GRK7—eye—Graves' disease	0.0171	0.0322	CbGeAlD
Ruxolitinib—GRK1—eye—Graves' disease	0.0124	0.0233	CbGeAlD
Ruxolitinib—PRKG2—pituitary gland—Graves' disease	0.00961	0.0181	CbGeAlD
Ruxolitinib—PRKCE—adipose tissue—Graves' disease	0.00894	0.0169	CbGeAlD
Ruxolitinib—RPS6KA6—pituitary gland—Graves' disease	0.00862	0.0163	CbGeAlD
Ruxolitinib—MAST1—pituitary gland—Graves' disease	0.00862	0.0163	CbGeAlD
Ruxolitinib—DCLK3—pituitary gland—Graves' disease	0.00817	0.0154	CbGeAlD
Ruxolitinib—PRKCE—thyroid gland—Graves' disease	0.00774	0.0146	CbGeAlD
Ruxolitinib—RPS6KA6—thyroid gland—Graves' disease	0.00743	0.014	CbGeAlD
Ruxolitinib—CAMK1D—eye—Graves' disease	0.00726	0.0137	CbGeAlD
Ruxolitinib—JAK3—connective tissue—Graves' disease	0.00721	0.0136	CbGeAlD
Ruxolitinib—PLK3—pituitary gland—Graves' disease	0.0072	0.0136	CbGeAlD
Ruxolitinib—PLK3—adipose tissue—Graves' disease	0.00717	0.0135	CbGeAlD
Ruxolitinib—JAK1—connective tissue—Graves' disease	0.00717	0.0135	CbGeAlD
Ruxolitinib—CAMK1—pituitary gland—Graves' disease	0.00673	0.0127	CbGeAlD
Ruxolitinib—CAMK1—adipose tissue—Graves' disease	0.0067	0.0126	CbGeAlD
Ruxolitinib—HIPK2—connective tissue—Graves' disease	0.00669	0.0126	CbGeAlD
Ruxolitinib—MARK2—adipose tissue—Graves' disease	0.00651	0.0123	CbGeAlD
Ruxolitinib—ROCK1—eye—Graves' disease	0.00641	0.0121	CbGeAlD
Ruxolitinib—PLK3—thyroid gland—Graves' disease	0.0062	0.0117	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—Graves' disease	0.00617	0.0116	CbGeAlD
Ruxolitinib—TAOK2—pituitary gland—Graves' disease	0.00605	0.0114	CbGeAlD
Ruxolitinib—TAOK2—adipose tissue—Graves' disease	0.00602	0.0114	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—Graves' disease	0.006	0.0113	CbGeAlD
Ruxolitinib—CAMK1—thyroid gland—Graves' disease	0.0058	0.0109	CbGeAlD
Ruxolitinib—MARK2—thyroid gland—Graves' disease	0.00563	0.0106	CbGeAlD
Ruxolitinib—CAMK2G—eye—Graves' disease	0.00557	0.0105	CbGeAlD
Ruxolitinib—JAK3—adipose tissue—Graves' disease	0.00553	0.0104	CbGeAlD
Ruxolitinib—JAK1—pituitary gland—Graves' disease	0.00552	0.0104	CbGeAlD
Ruxolitinib—DCLK1—pituitary gland—Graves' disease	0.00552	0.0104	CbGeAlD
Ruxolitinib—JAK1—adipose tissue—Graves' disease	0.0055	0.0104	CbGeAlD
Ruxolitinib—DCLK1—adipose tissue—Graves' disease	0.0055	0.0104	CbGeAlD
Ruxolitinib—CAMK1D—pituitary gland—Graves' disease	0.00539	0.0102	CbGeAlD
Ruxolitinib—CAMK1D—adipose tissue—Graves' disease	0.00537	0.0101	CbGeAlD
Ruxolitinib—BMP2K—connective tissue—Graves' disease	0.00537	0.0101	CbGeAlD
Ruxolitinib—PHKG2—adipose tissue—Graves' disease	0.00534	0.0101	CbGeAlD
Ruxolitinib—DAPK2—adipose tissue—Graves' disease	0.00525	0.00989	CbGeAlD
Ruxolitinib—TAOK2—thyroid gland—Graves' disease	0.00521	0.00983	CbGeAlD
Ruxolitinib—STK16—pituitary gland—Graves' disease	0.00518	0.00977	CbGeAlD
Ruxolitinib—STK16—adipose tissue—Graves' disease	0.00516	0.00973	CbGeAlD
Ruxolitinib—HIPK2—adipose tissue—Graves' disease	0.00513	0.00968	CbGeAlD
Ruxolitinib—DAPK3—pituitary gland—Graves' disease	0.00495	0.00934	CbGeAlD
Ruxolitinib—DAPK3—adipose tissue—Graves' disease	0.00493	0.0093	CbGeAlD
Ruxolitinib—TYK2—eye—Graves' disease	0.00492	0.00928	CbGeAlD
Ruxolitinib—CLK2—pituitary gland—Graves' disease	0.00491	0.00925	CbGeAlD
Ruxolitinib—CLK2—adipose tissue—Graves' disease	0.00489	0.00921	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—Graves' disease	0.00487	0.00919	CbGeAlD
Ruxolitinib—MKNK2—eye—Graves' disease	0.00485	0.00916	CbGeAlD
Ruxolitinib—JAK3—thyroid gland—Graves' disease	0.00479	0.00903	CbGeAlD
Ruxolitinib—JAK1—thyroid gland—Graves' disease	0.00476	0.00898	CbGeAlD
Ruxolitinib—DCLK1—thyroid gland—Graves' disease	0.00476	0.00898	CbGeAlD
Ruxolitinib—TYK2—connective tissue—Graves' disease	0.00474	0.00894	CbGeAlD
Ruxolitinib—MKNK2—connective tissue—Graves' disease	0.00468	0.00882	CbGeAlD
Ruxolitinib—CAMK1D—thyroid gland—Graves' disease	0.00465	0.00876	CbGeAlD
Ruxolitinib—BMPR2—pituitary gland—Graves' disease	0.00462	0.00871	CbGeAlD
Ruxolitinib—PHKG2—thyroid gland—Graves' disease	0.00462	0.00871	CbGeAlD
Ruxolitinib—DYRK1A—adipose tissue—Graves' disease	0.00462	0.00871	CbGeAlD
Ruxolitinib—BMPR2—adipose tissue—Graves' disease	0.0046	0.00868	CbGeAlD
Ruxolitinib—RET—connective tissue—Graves' disease	0.00456	0.0086	CbGeAlD
Ruxolitinib—DAPK2—thyroid gland—Graves' disease	0.00454	0.00856	CbGeAlD
Ruxolitinib—STK16—thyroid gland—Graves' disease	0.00447	0.00842	CbGeAlD
Ruxolitinib—HIPK2—thyroid gland—Graves' disease	0.00444	0.00838	CbGeAlD
Ruxolitinib—NUAK2—pituitary gland—Graves' disease	0.00441	0.00832	CbGeAlD
Ruxolitinib—NUAK2—adipose tissue—Graves' disease	0.0044	0.00829	CbGeAlD
Ruxolitinib—JAK2—connective tissue—Graves' disease	0.00431	0.00813	CbGeAlD
Ruxolitinib—DAPK3—thyroid gland—Graves' disease	0.00427	0.00805	CbGeAlD
Ruxolitinib—CLK2—thyroid gland—Graves' disease	0.00423	0.00798	CbGeAlD
Ruxolitinib—CAMK2G—pituitary gland—Graves' disease	0.00413	0.0078	CbGeAlD
Ruxolitinib—CAMK2G—adipose tissue—Graves' disease	0.00412	0.00776	CbGeAlD
Ruxolitinib—BMP2K—adipose tissue—Graves' disease	0.00412	0.00776	CbGeAlD
Ruxolitinib—LRRK2—pituitary gland—Graves' disease	0.0041	0.00773	CbGeAlD
Ruxolitinib—LRRK2—adipose tissue—Graves' disease	0.00408	0.00769	CbGeAlD
Ruxolitinib—DYRK1A—thyroid gland—Graves' disease	0.004	0.00754	CbGeAlD
Ruxolitinib—BMPR2—thyroid gland—Graves' disease	0.00398	0.00751	CbGeAlD
Ruxolitinib—TAOK3—eye—Graves' disease	0.00393	0.00742	CbGeAlD
Ruxolitinib—NUAK2—thyroid gland—Graves' disease	0.00381	0.00718	CbGeAlD
Ruxolitinib—TAOK3—connective tissue—Graves' disease	0.00379	0.00715	CbGeAlD
Ruxolitinib—MAP3K2—adipose tissue—Graves' disease	0.00374	0.00705	CbGeAlD
Ruxolitinib—MAP3K7—pituitary gland—Graves' disease	0.00372	0.00701	CbGeAlD
Ruxolitinib—MAP3K7—adipose tissue—Graves' disease	0.0037	0.00698	CbGeAlD
Ruxolitinib—TYK2—pituitary gland—Graves' disease	0.00365	0.00689	CbGeAlD
Ruxolitinib—TYK2—adipose tissue—Graves' disease	0.00364	0.00686	CbGeAlD
Ruxolitinib—MKNK2—pituitary gland—Graves' disease	0.0036	0.0068	CbGeAlD
Ruxolitinib—MKNK2—adipose tissue—Graves' disease	0.00359	0.00677	CbGeAlD
Ruxolitinib—IRAK1—adipose tissue—Graves' disease	0.00359	0.00677	CbGeAlD
Ruxolitinib—CAMK2G—thyroid gland—Graves' disease	0.00356	0.00672	CbGeAlD
Ruxolitinib—BMP2K—thyroid gland—Graves' disease	0.00356	0.00672	CbGeAlD
Ruxolitinib—LRRK2—thyroid gland—Graves' disease	0.00353	0.00666	CbGeAlD
Ruxolitinib—RET—pituitary gland—Graves' disease	0.00351	0.00663	CbGeAlD
Ruxolitinib—JAK2—pituitary gland—Graves' disease	0.00332	0.00626	CbGeAlD
Ruxolitinib—JAK2—adipose tissue—Graves' disease	0.00331	0.00624	CbGeAlD
Ruxolitinib—MAP3K2—thyroid gland—Graves' disease	0.00324	0.0061	CbGeAlD
Ruxolitinib—MAP3K7—thyroid gland—Graves' disease	0.00321	0.00604	CbGeAlD
Ruxolitinib—MAP3K3—pituitary gland—Graves' disease	0.0032	0.00604	CbGeAlD
Ruxolitinib—MAP3K3—adipose tissue—Graves' disease	0.00319	0.00601	CbGeAlD
Ruxolitinib—TYK2—thyroid gland—Graves' disease	0.00315	0.00594	CbGeAlD
Ruxolitinib—IRAK1—thyroid gland—Graves' disease	0.00311	0.00586	CbGeAlD
Ruxolitinib—MKNK2—thyroid gland—Graves' disease	0.00311	0.00586	CbGeAlD
Ruxolitinib—RET—thyroid gland—Graves' disease	0.00303	0.00571	CbGeAlD
Ruxolitinib—TAOK3—pituitary gland—Graves' disease	0.00292	0.0055	CbGeAlD
Ruxolitinib—TAOK3—adipose tissue—Graves' disease	0.00291	0.00548	CbGeAlD
Ruxolitinib—JAK2—thyroid gland—Graves' disease	0.00286	0.0054	CbGeAlD
Ruxolitinib—MAP3K3—thyroid gland—Graves' disease	0.00276	0.0052	CbGeAlD
Ruxolitinib—TAOK3—thyroid gland—Graves' disease	0.00252	0.00475	CbGeAlD
Ruxolitinib—ROCK1—Apoptosis—TNF—Graves' disease	0.000262	0.000557	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-E—Graves' disease	0.000262	0.000557	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.000259	0.000551	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	0.000258	0.000549	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000256	0.000545	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000256	0.000545	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD40—Graves' disease	0.000256	0.000544	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Developmental Biology—TNF—Graves' disease	0.000254	0.000541	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CTLA4—Graves' disease	0.000252	0.000536	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CXCL10—Graves' disease	0.000252	0.000536	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.000251	0.000534	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—CXCL10—Graves' disease	0.00025	0.000532	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000248	0.000529	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HLA-E—Graves' disease	0.000248	0.000528	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—IL1B—Graves' disease	0.000246	0.000524	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—HLA-A—Graves' disease	0.000246	0.000523	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—IL2RA—Graves' disease	0.000242	0.000515	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IFIH1—Graves' disease	0.000241	0.000514	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000241	0.000513	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HLA-E—Graves' disease	0.000241	0.000512	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-E—Graves' disease	0.00024	0.00051	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD40—Graves' disease	0.000234	0.000498	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-E—Graves' disease	0.000234	0.000498	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HLA-E—Graves' disease	0.000233	0.000497	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—CXCL10—Graves' disease	0.000232	0.000495	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HLA-B—Graves' disease	0.000232	0.000494	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IFIH1—Graves' disease	0.000232	0.000494	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-B—Graves' disease	0.000232	0.000493	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CTLA4—Graves' disease	0.000231	0.000491	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD40—Graves' disease	0.000229	0.000487	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TSHR—Graves' disease	0.000229	0.000487	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.000228	0.000486	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CXCL10—Graves' disease	0.000228	0.000484	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CTLA4—Graves' disease	0.000225	0.00048	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-E—Graves' disease	0.000224	0.000477	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-E—Graves' disease	0.000221	0.00047	CbGpPWpGaD
Ruxolitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	0.000221	0.00047	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD40—Graves' disease	0.000219	0.000466	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.000217	0.000462	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CTLA4—Graves' disease	0.000216	0.00046	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD40—Graves' disease	0.000216	0.000459	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.000215	0.000457	CbGpPWpGaD
Ruxolitinib—JAK2—Interferon Signaling—IFNG—Graves' disease	0.000215	0.000457	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CTLA4—Graves' disease	0.000213	0.000453	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—B3GNT2—Graves' disease	0.000211	0.000449	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—CXCL10—Graves' disease	0.000211	0.000449	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—IL2RA—Graves' disease	0.00021	0.000448	CbGpPWpGaD
Ruxolitinib—MAP3K7—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	0.000208	0.000442	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-DQB1—Graves' disease	0.000207	0.000442	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—TSHR—Graves' disease	0.000207	0.000442	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL2RA—Graves' disease	0.000205	0.000435	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—CXCL10—Graves' disease	0.0002	0.000426	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—CXCL10—Graves' disease	0.000197	0.000419	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.000196	0.000418	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000195	0.000415	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD8A—Graves' disease	0.000194	0.000412	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TSHR—Graves' disease	0.000193	0.000411	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL2RA—Graves' disease	0.000192	0.000409	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL2RA—Graves' disease	0.000191	0.000407	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—CD4—Graves' disease	0.000191	0.000407	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-DQB1—Graves' disease	0.00019	0.000405	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-E—Graves' disease	0.00019	0.000404	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000189	0.000402	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000188	0.000401	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-B—Graves' disease	0.000186	0.000397	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-DQB1—Graves' disease	0.000186	0.000395	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD40—Graves' disease	0.000186	0.000395	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFIH1—Graves' disease	0.000184	0.000391	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000183	0.00039	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CTLA4—Graves' disease	0.000183	0.000389	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HLA-E—Graves' disease	0.000182	0.000388	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CXCL10—Graves' disease	0.000182	0.000386	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TNF—Graves' disease	0.000179	0.00038	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CXCL10—Graves' disease	0.000179	0.00038	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFIH1—Graves' disease	0.000178	0.000379	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000178	0.000379	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—IL2RA—Graves' disease	0.000178	0.000378	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD8A—Graves' disease	0.000177	0.000378	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HLA-B—Graves' disease	0.000177	0.000376	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-DQB1—Graves' disease	0.000175	0.000373	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—CD4—Graves' disease	0.000175	0.000372	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL2RA—Graves' disease	0.000175	0.000372	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL2RA—Graves' disease	0.000174	0.00037	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.000174	0.00037	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD8A—Graves' disease	0.000173	0.000369	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—TSHR—Graves' disease	0.000173	0.000368	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFIH1—Graves' disease	0.000173	0.000368	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-A—Graves' disease	0.000173	0.000368	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HLA-B—Graves' disease	0.000171	0.000365	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-B—Graves' disease	0.000171	0.000363	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.000169	0.000359	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-B—Graves' disease	0.000167	0.000355	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HLA-B—Graves' disease	0.000166	0.000354	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD8A—Graves' disease	0.000166	0.000353	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TSHR—Graves' disease	0.000166	0.000353	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.000164	0.000348	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD8A—Graves' disease	0.000163	0.000348	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TSHR—Graves' disease	0.000163	0.000347	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL2RA—Graves' disease	0.000161	0.000343	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—B3GNT2—Graves' disease	0.00016	0.000341	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL2RA—Graves' disease	0.00016	0.00034	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-B—Graves' disease	0.00016	0.00034	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HLA-A—Graves' disease	0.000159	0.000339	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—CD4—Graves' disease	0.000158	0.000337	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-A—Graves' disease	0.000158	0.000337	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-DRB1—Graves' disease	0.000158	0.000336	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-B—Graves' disease	0.000157	0.000335	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—TSHR—Graves' disease	0.000157	0.000335	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL2RA—Graves' disease	0.000156	0.000333	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-A—Graves' disease	0.000154	0.000329	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—IL2RA—Graves' disease	0.000153	0.000325	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—ICAM1—Graves' disease	0.000151	0.000322	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-DQB1—Graves' disease	0.000151	0.000321	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—IL2RA—Graves' disease	0.00015	0.00032	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-A—Graves' disease	0.000148	0.000315	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CXCL10—Graves' disease	0.000148	0.000314	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL2RA—Graves' disease	0.000147	0.000314	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-A—Graves' disease	0.000146	0.00031	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-DRB1—Graves' disease	0.000144	0.000308	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-E—Graves' disease	0.000144	0.000307	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000143	0.000305	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-DRB1—Graves' disease	0.000141	0.0003	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD40—Graves' disease	0.000141	0.0003	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD8A—Graves' disease	0.000141	0.000299	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-E—Graves' disease	0.00014	0.000298	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CTLA4—Graves' disease	0.000139	0.000296	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL2RA—Graves' disease	0.000139	0.000295	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—CD4—Graves' disease	0.000139	0.000295	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—ICAM1—Graves' disease	0.000139	0.000295	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD40—Graves' disease	0.000137	0.000292	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL2RA—Graves' disease	0.000136	0.000291	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-E—Graves' disease	0.000136	0.000289	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—ICAM1—Graves' disease	0.000135	0.000288	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-B—Graves' disease	0.000135	0.000288	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IL2RA—Graves' disease	0.000135	0.000288	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000135	0.000288	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFIH1—Graves' disease	0.000135	0.000287	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTLA4—Graves' disease	0.000135	0.000287	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CXCL10—Graves' disease	0.000134	0.000285	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-DRB1—Graves' disease	0.000133	0.000283	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD40—Graves' disease	0.000133	0.000283	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTLA4—Graves' disease	0.000131	0.000279	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HLA-B—Graves' disease	0.00013	0.000277	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—ICAM1—Graves' disease	0.00013	0.000276	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.000128	0.000272	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—ICAM1—Graves' disease	0.000128	0.000272	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL2RA—Graves' disease	0.000127	0.00027	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TSHR—Graves' disease	0.000126	0.000269	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-A—Graves' disease	0.000125	0.000267	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCL10—Graves' disease	0.000125	0.000265	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TSHR—Graves' disease	0.000123	0.000261	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TSHR—Graves' disease	0.000119	0.000253	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HLA-A—Graves' disease	0.000116	0.000246	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IFNG—Graves' disease	0.000115	0.000245	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-DQB1—Graves' disease	0.000115	0.000244	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-DRB1—Graves' disease	0.000115	0.000244	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL2RA—Graves' disease	0.000113	0.00024	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL10—Graves' disease	0.000112	0.000238	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD4—Graves' disease	0.000111	0.000237	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-DQB1—Graves' disease	0.000111	0.000237	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—ICAM1—Graves' disease	0.00011	0.000234	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-DQB1—Graves' disease	0.000108	0.00023	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL10—Graves' disease	0.000107	0.000228	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD8A—Graves' disease	0.000107	0.000228	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-E—Graves' disease	0.000106	0.000226	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IFNG—Graves' disease	0.000106	0.000225	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL10—Graves' disease	0.000105	0.000225	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CD4—Graves' disease	0.000105	0.000225	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TNF—Graves' disease	0.000105	0.000224	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD40—Graves' disease	0.000104	0.000221	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD8A—Graves' disease	0.000104	0.000221	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TNF—Graves' disease	0.000104	0.00022	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IFNG—Graves' disease	0.000103	0.000219	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-B—Graves' disease	0.000103	0.000219	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1B—Graves' disease	0.000103	0.000219	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CD4—Graves' disease	0.000103	0.000219	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2RA—Graves' disease	0.000102	0.000218	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CD4—Graves' disease	0.000102	0.000218	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTLA4—Graves' disease	0.000102	0.000218	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD4—Graves' disease	0.000102	0.000217	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL10—Graves' disease	0.000102	0.000216	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD8A—Graves' disease	0.000101	0.000214	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-B—Graves' disease	9.99e-05	0.000213	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD4—Graves' disease	9.95e-05	0.000212	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CD4—Graves' disease	9.93e-05	0.000211	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IFNG—Graves' disease	9.72e-05	0.000207	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-B—Graves' disease	9.69e-05	0.000206	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2RA—Graves' disease	9.64e-05	0.000205	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD4—Graves' disease	9.54e-05	0.000203	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-A—Graves' disease	9.53e-05	0.000203	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2RA—Graves' disease	9.53e-05	0.000203	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1B—Graves' disease	9.41e-05	0.0002	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD4—Graves' disease	9.39e-05	0.0002	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2RA—Graves' disease	9.36e-05	0.000199	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TSHR—Graves' disease	9.29e-05	0.000198	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-A—Graves' disease	9.25e-05	0.000197	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1B—Graves' disease	9.19e-05	0.000196	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2RA—Graves' disease	9.08e-05	0.000193	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-A—Graves' disease	8.98e-05	0.000191	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-DRB1—Graves' disease	8.71e-05	0.000185	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1B—Graves' disease	8.67e-05	0.000185	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2RA—Graves' disease	8.55e-05	0.000182	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HLA-A—Graves' disease	8.54e-05	0.000182	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-DRB1—Graves' disease	8.45e-05	0.00018	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DQB1—Graves' disease	8.43e-05	0.000179	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IFNG—Graves' disease	8.36e-05	0.000178	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ICAM1—Graves' disease	8.36e-05	0.000178	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-DRB1—Graves' disease	8.2e-05	0.000175	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2RA—Graves' disease	8.2e-05	0.000174	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL10—Graves' disease	8.16e-05	0.000174	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ICAM1—Graves' disease	8.11e-05	0.000173	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD4—Graves' disease	8.08e-05	0.000172	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2RA—Graves' disease	8.06e-05	0.000172	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL10—Graves' disease	7.92e-05	0.000169	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ICAM1—Graves' disease	7.87e-05	0.000168	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD8A—Graves' disease	7.87e-05	0.000168	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—Graves' disease	7.77e-05	0.000165	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2RA—Graves' disease	7.76e-05	0.000165	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CD4—Graves' disease	7.76e-05	0.000165	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL10—Graves' disease	7.68e-05	0.000163	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-B—Graves' disease	7.57e-05	0.000161	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1B—Graves' disease	7.46e-05	0.000159	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD4—Graves' disease	7.46e-05	0.000159	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2RA—Graves' disease	7.09e-05	0.000151	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-A—Graves' disease	7.01e-05	0.000149	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HLA-A—Graves' disease	6.48e-05	0.000138	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DRB1—Graves' disease	6.41e-05	0.000136	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNG—Graves' disease	6.36e-05	0.000135	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2RA—Graves' disease	6.23e-05	0.000133	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNG—Graves' disease	6.17e-05	0.000131	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ICAM1—Graves' disease	6.15e-05	0.000131	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD4—Graves' disease	6.14e-05	0.000131	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2RA—Graves' disease	6.05e-05	0.000129	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL10—Graves' disease	6e-05	0.000128	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNG—Graves' disease	5.99e-05	0.000127	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD4—Graves' disease	5.96e-05	0.000127	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—Graves' disease	5.89e-05	0.000125	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2RA—Graves' disease	5.87e-05	0.000125	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD4—Graves' disease	5.78e-05	0.000123	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—Graves' disease	5.67e-05	0.000121	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—Graves' disease	5.51e-05	0.000117	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD4—Graves' disease	5.51e-05	0.000117	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—Graves' disease	5.34e-05	0.000114	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GC—Graves' disease	5e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—Graves' disease	4.68e-05	9.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2RA—Graves' disease	4.59e-05	9.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—Graves' disease	4.52e-05	9.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—Graves' disease	4.17e-05	8.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—Graves' disease	4.17e-05	8.88e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—B3GNT2—Graves' disease	3.79e-05	8.06e-05	CbGpPWpGaD
